Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

debenture 4,000,000 - 4,000,000 -

Exercise of stock

options - 10,000 31,750 14,500

Repayment of

long-term debt (158,038) (191,843) (310,584) (375,812)

Proceeds from

long-term debt - - 634,900 -

Repayment of

repayable advances - - - (85,640)

------------ ------------ ------------ ------------

Cash provided by

(used in) financing

activities 3,841,962 (350,782) 4,298,182 13,932,058

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Investing activities

Proceeds on sale of

property and

equipment - 6,000 - 6,000

Acquisition of

property and

equipment (478,806) (1,973,020) (1,023,650) (2,417,836)

------------ ------------ ------------ ------------

Cash used in

investing activities (478,806) (1,967,020) (1,023,650) (2,411,836)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Increase (decrease)

in cash and cash

equivalents (2,182,855) (5,928,153) (6,342,090) 6,549,325

Cash and cash

equivalents -

Beginning of period 16,284,778 28,805,937 20,444,013 16,328,459

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Cash and cash

equivalents - End

of period 14,101,923 22,877,784 14,101,923 22,877,784


'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7Reportlinker Adds Pharmacodynamic Assays 2Reportlinker Adds Pharmacodynamic Assays 3Reportlinker Adds Pharmacodynamic Assays 4SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3